Same-side insufficiency fractures of the tibia and femur after denosumab discontinuation: a case report
Same-side insufficiency fractures of the tibia and femur after denosumab discontinuation: a case report
复制标题
停用狄诺塞麦后发生同侧胫骨和股骨不全骨折：病例报告
DOI：
10.1080/24725625.2020.1832756
复制
发表时间：
2020
影响因子：
0.8
通讯作者：
Taguchi Akira
中科院分区：
文献类型：
--
作者：
Koiwai Hidefumi;Kamimura Mikio;Nakamura Yukio;Takahashi Jun;Taguchi Akira
骨质疏松症（OP）是老年人常见的疾病，可导致骨折并增加死亡率。狄诺塞麦（DMAB）是治疗OP的几种药物之一。DMAB不仅可以降低骨折的风险，还可以提高生活质量。然而，据报道，DMAB停药后多发性椎骨骨折的风险增加。我们描述了一个罕见的情况下，71岁的妇女与严重的OP谁经历了同侧不足骨折的胫骨和股骨在18个月后DMAB停止。DMAB停药后，建议仔细监测脊椎和下肢脆性骨折。
Osteoporosis (OP) is a common disease in the elderly that causes bone fractures and increases mortality. Denosumab (DMAB) is one of several medications to treat OP. DMAB not only reduces the risk of fractures, but also improves the quality of life. However, an increase in the risk of multiple vertebral fractures has been reported after DMAB discontinuation. We described the rare case of a 71-year-old woman with severe OP who experienced same-side insufficiency fractures of the tibia and femur at 18 months after DMAB discontinuation. Careful monitoring for both vertebral and lower limb fragility fractures is advised after DMAB cessation.
停用狄诺塞麦后 6 个月内骨密度显着下降：病例报告
影响因子：
0.8
作者：
Yusuke Maezumi;M. Kamimura;Yukio Nakamura;J. Takahashi
通讯作者：
J. Takahashi
影响因子：
6.2
作者：
Cummings, Steven R.;Ferrari, Serge;Brown, Jacques P.
通讯作者：
Brown, Jacques P.
【如何应对狄诺塞麦停药后的反弹效应，避免多发椎体骨折？】
影响因子：
--
作者：
E. Gonzalez Rodriguez;O. Lamy;B. Aubry;D. Stoll;B. Uebelhart
通讯作者：
B. Uebelhart